Digestive Diseases and Sciences

, Volume 54, Issue 4, pp 862–868 | Cite as

Association of Visceral Fat Accumulation and Adiponectin Levels with Colorectal Neoplasia

  • Elife Erarslan
  • Cansel Turkay
  • Aslý Koktener
  • Cemile Koca
  • Burak Uz
  • Nuket Bavbek
Original Article

Abstract

Purpose There are few studies addressing the association between measured values of visceral fat accumulation (VFA), adiponectin, and colorectal neoplasia. Our purpose is to investigate the association of VFA and serum adiponectin levels with colorectal adenoma and carcinoma patients. For this purpose, 54 patients with colorectal adenoma and carcinoma, diagnosed by colonoscopic evaluation, and 50 healthy control subjects were included. Patients were subjected to measurement of VFA and adiponectin level and calculation of insulin resistance. Results Patients with colorectal carcinoma had lower plasma adiponectin levels compared with controls. VFA level did not differ between patients and controls. Adiponectin level was found to be uncorrelated with VFA in the colorectal cancer and adenoma group. No correlation was found between insulin resistance and plasma adiponectin level and VFA. Conclusion Our findings suggest that decreased plasma adiponectin level may be a factor involved in the development of colon cancer or a secondary effect of the metabolic derangements in colorectal cancer.

Keywords

Adiponectin Obesity VFA Colon Cancer Adenoma 

Notes

Acknowledgments

This work is supported by the Scientific Research Fund of Fatih University under project number P53010714.

References

  1. 1.
    MacInnis RJ, English DR, Hopper JL, Gertig DM, Haydon M, Giles GG. Body size and composition and colon cancer risk in women. Int J Cancer. 2006;118:1496–1500. doi: 10.1002/ijc.21508.PubMedCrossRefGoogle Scholar
  2. 2.
    Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European prospective investigation into cancer and nutrition (EPIC). Natl Cancer Inst. 2006;98(13):920–931.PubMedCrossRefGoogle Scholar
  3. 3.
    MacInnis RJ, English DR, Haydon AM, Hopper JL, Gertig DM, Giles GG. Body size and composition and risk of rectal cancer (Australia). Cancer Causes Control. 2006;17:1291–1297. doi: 10.1007/s10552-006-0074-y.PubMedCrossRefGoogle Scholar
  4. 4.
    Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and indent colorectal cancer. J Natl Cancer Inst. 1999;91:1147–1154. doi: 10.1093/jnci/91.13.1147.PubMedCrossRefGoogle Scholar
  5. 5.
    Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism. 1987;36:54–59. doi: 10.1016/0026-0495(87)90063-1.PubMedCrossRefGoogle Scholar
  6. 6.
    Shuman WP, Morris LL, Leonetti DL, et al. Abnormal body fat distribution detected by computed tomography in diabetic men. Invest Radiol. 1986;21:483–487. doi: 10.1097/00004424-198606000-00007.PubMedCrossRefGoogle Scholar
  7. 7.
    Seidell JC, Oosterlee A, Thijssen MA, et al. Assessment of intra-abdominal and subcutaneous abdominal fat: relation between anthropometry and computed tomography. Am J Clin Nutr. 1987;45:7–13.PubMedGoogle Scholar
  8. 8.
    Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595–1599.PubMedGoogle Scholar
  9. 9.
    Kumada M, Kihara S, Sumitsuji S, et al. Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85–89. doi: 10.1161/01.ATV.0000048856.22331.50.
  10. 10.
    Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem. 2003;278:9073–9085. doi: 10.1074/jbc.M207198200.PubMedCrossRefGoogle Scholar
  11. 11.
    Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279:12152–12162. doi: 10.1074/jbc.M311113200.PubMedCrossRefGoogle Scholar
  12. 12.
    Maeda N, Shimomura I, Kishida K, et al. Diet induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8:731–737. doi: 10.1038/nm724.PubMedCrossRefGoogle Scholar
  13. 13.
    Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–1295. doi: 10.1038/nm788.PubMedCrossRefGoogle Scholar
  14. 14.
    Zietz B, Herfarth H, Paul G, et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett. 2003;19:103–104. doi: 10.1016/S0014-5793(03)00568-4.CrossRefGoogle Scholar
  15. 15.
    Thamer C, Haap M, Bachmann O, et al. Serum adiponectin levels predict the effect of short-term dietary inter ventions on insulin sensitivity in humans. Diabetologia. 2004;47:1303–1305. doi: 10.1007/s00125-004-1430-7.PubMedCrossRefGoogle Scholar
  16. 16.
    Dal Maso L, Augustın LSA, Karalıs A, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab. 2004;89(3):1160–1163. doi: 10.1210/jc.2003-031716.PubMedCrossRefGoogle Scholar
  17. 17.
    Miyoshi Y, Funahashi T, Kihara S, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;15:5699–5704.Google Scholar
  18. 18.
    Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA. 2004;101:2476–2481. doi: 10.1073/pnas.0308671100.PubMedCrossRefGoogle Scholar
  19. 19.
    Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000;96:1723–1732.PubMedGoogle Scholar
  20. 20.
    Nieves DJ, Cnop M, Retzlaff B, et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes. 2003;52:172–179. doi: 10.2337/diabetes.52.1.172.PubMedCrossRefGoogle Scholar
  21. 21.
    Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J. 2006;70:1437–1442. doi: 10.1253/circj.70.1437.PubMedCrossRefGoogle Scholar
  22. 22.
    Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395:763–770. doi: 10.1038/27376.PubMedCrossRefGoogle Scholar
  23. 23.
    Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29–33. doi: 10.1161/01.ATV.0000099786.99623.EF.PubMedCrossRefGoogle Scholar
  24. 24.
    Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood streamand adipose tissue. Circulation. 2003;107:671. doi: 10.1161/01.CIR.0000055188.83694.B3.PubMedCrossRefGoogle Scholar
  25. 25.
    Engeli S, Feldpausch M, Gorzelniak K, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes. 2003;52:942–947. doi: 10.2337/diabetes.52.4.942.PubMedCrossRefGoogle Scholar
  26. 26.
    Otake S, Takeda H, Suzuki Y, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res. 2005;11:3642–3646. doi: 10.1158/1078-0432.CCR-04-1868.PubMedCrossRefGoogle Scholar
  27. 27.
    The Expert Committee. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:11833–11197.Google Scholar
  28. 28.
    Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57–63. doi: 10.2337/diacare.23.1.57.PubMedCrossRefGoogle Scholar
  29. 29.
    Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case–control study in Greece. J Clin Endocrinol Metab. 2003;88(3):993–997. doi: 10.1210/jc.2002-021209.PubMedCrossRefGoogle Scholar
  30. 30.
    Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97:1688–1694.PubMedGoogle Scholar
  31. 31.
    Michalakis K, Catherine J, Williams L, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev. 2007;16(2). doi: 10.1158/1055-9965.EPI-06-0621.
  32. 32.
    Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed). 1984;288:1401–1404.Google Scholar
  33. 33.
    Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982;54:254–260.PubMedCrossRefGoogle Scholar
  34. 34.
    Folsom AR, Kaye SA, Sellers TA, et al. Body fat distribution and 5-year risk of death in older women [published erratum appears in JAMA. 1993;269:1254].Google Scholar
  35. 35.
    Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer:the Women’s Health Initiative (United States). Cancer Causes Control. 2002;13:741–751. doi: 10.1023/A:1020239211145.PubMedCrossRefGoogle Scholar
  36. 36.
    Von Hafe P, Pina F, Pe’rez A, Tavares M, Barros H. Visceral fat accumulation as a risk factor for prostate cancer. Obes Res. 2004;12:1930–1935. doi: 10.1038/oby.2004.242.CrossRefGoogle Scholar
  37. 37.
    Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89:1102–1107. doi: 10.1210/jc.2003-031804.PubMedCrossRefGoogle Scholar
  38. 38.
    Lee HL, Son BK, Lee OY, et al. Abdominal obesity, insulin resistance, and the risk of colonic adenoma. Korean J Gastroenterol. 2007;49(3):147–151.PubMedGoogle Scholar
  39. 39.
    Nishii T, Kono S, Abe H, et al. Glucose intolerance, plasma insulin levels, and colon adenomas in Japanese. Jpn J Cancer Res. 2001;92:836–840.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Elife Erarslan
    • 1
    • 2
  • Cansel Turkay
    • 1
  • Aslý Koktener
    • 3
  • Cemile Koca
    • 4
  • Burak Uz
    • 5
  • Nuket Bavbek
    • 5
  1. 1.Department of GastroenterologyFatih University Medical SchoolAnkaraTurkey
  2. 2.AnkaraTurkey
  3. 3.Department of RadiologyFatih University Medical SchoolAnkaraTurkey
  4. 4.Department of Clinic BiochemistryFatih University Medical SchoolAnkaraTurkey
  5. 5.Department of Internal MedicineFatih University Medical SchoolAnkaraTurkey

Personalised recommendations